Secondary structure of amyloid β peptide correlates with neurotoxic activity in vitro

Molecular Pharmacology

Volumn 45, Issue 3, 1994, Pages 373-379

  Simmons, Linda K ^a   May, Patrick C ^a   Tomaselli, Kevin J ^b   Rydel, Russell E ^b   Fuson, Kimberly S ^a   Brigham, Elizabeth F ^b   Wright, Sarah ^b   Lieberburg, Ivan ^b   Becker, Gerald W ^a   Brems, David N ^a   Li, Wei Ying ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Athena Neurosciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

ALPHA CHAIN; ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BETA CHAIN; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; HIPPOCAMPUS; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PH; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; RAT;

AMYLOID BETA-PROTEIN; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; CIRCULAR DICHROISM; HYDROGEN-ION CONCENTRATION; NEURONS; PROTEIN STRUCTURE, SECONDARY; RATS;

EID: 0028265912     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Katzman, R. Alzheimer's disease. N. Engl. J. Med. 314:964-972 (1986).
2. Selkoe, D. J. Biochemistry of altered brain proteins in Alzheimer's disease. Annu. Rev. Neurosci. 12:463-490 (1989).
3. Glenner, G. G., and C. W. Wong. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120:885-890 (1984).
4. Kang, J., H.-G. Lemaire, A. Unterbeck, J. M. Salbaum, C. L. Masters, K. H. Grzeschik, G. Multhaup, K. Beyreuther, and B. Muller-Hill. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature (Lond.) 325:733-736.
5. Jarrett, J. T., E. P. Berger, and P. T. Lansbury, Jr. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32:4693-4697 (1993).
6. Barrow, C. J., A. Yasuda, P. T. M. Kenny, and M. G. Zagorski. Solution conformations and aggregational properties of synthetic amyloid β-peptides of Alzheimer's disease: analysis of circular dichroism spectra. J. Mol. Biol. 225:1075-1093 (1992).
7. Wisniewski, K., H. Wisniewski, and G. Wen. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 17:278-282 (1985).
8. Murrell, J., M. Farlow, B. Ghetti, and M. Benson. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science (Washington D. C.) 254:97-99 (1991).
9. Goate, A., M.-C. Chartier-Harlin, M. Mullan, J. Brown, F. Crawford, L. Fidani, L. Giuffra, A. Haynes, N. Irving, L. James, R. Mant, P. Newton, K. Rooke, P. Roques, C. Talbot, M. Pericak-Vance, A. Roses, R. Williamson, M. Rossor, and J. Hardy. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (Lond.) 349:704-706 (1991).
10. Yankner, B. A., L. K. Duffy, and D. A. Kirschner. Neurotropic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science (Washington D. C.) 250:279-282 (1990).
11. Whitson, J. S., D. J. Selkoe, and C. W. Cotman. Amyloid protein enhances the survival of hippocampal neurons in vitro. Science ( Washington D. C. ) 243:1488-1490 (1989).
12. Roher, A. E., M. J. Ball, S. V. Bhave, and A. R. Wakade. β-Amyloid from Alzheimer disease brains inhibits sprouting and survival of sympathetic neurons. Biochem. Biophys. Res. Commun. 174:572-579 (1991).
13. Mattson, M. P., B. Cheng, D. Davis, K. Bryant, I. Lieberburg, and R. Rydel. β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12:376-389 (1992).
14. May, P. C., B. D. Gitter, D. C. Waters, L. K. Simmons, G. W. Becker, J. S. Small, and P. M. Robison. β-Amyloid in vitro toxicity: lot-to-lot variability. Neurobiol. Aging 13:605-607 (1992).
15. Busciglio, J., A. Lorenzo, and B. A. Yankner. Methodological variables in the assessment of beta-amyloid neurotoxicity. Neurobiol. Aging 13:609-612 (1992).
16. Pike, C. J., D. Burdick, A. J. Walencewicz, C. G. Glabe, and C. W. Cotman. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13:1676-1687 (1993).
17. Mattson, M. P., K. J. Tomasselli, and R. E. Rydel. Calcium-destabilizing and neurodegenerative effects of aggregated β-amyloid are attenuated by basic FGF. Brain Res. 621:35-49 (1993).
18. Halverson, K., P. E. Frazier, D. A. Kirschner, and P. T. Lansbury, Jr. Molecular determinants of amyloid deposition in Alzheimer's disease: conformational studies of synthetic β-protein fragments. Biochemistry 29:2693-2644 (1990).
19. Woody, R. M. Circular dichroism of peptides, in The Peptides (V. J. Hruby, ed.), Vol. 7. Academic Press, New York, 15-115 (1985).
20. 2+ in cerebral cortex neurons is transient in immature cells but permanent in mature cells. J. Neurochem. 53: 1316-1319 (1989).
21. Roehm, N. W., G. H. Rodgers, S. M. Hatfield, and A. L. Glasebrook. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J. Immunol Methods 142:257-265 (1991).
22. Barrow, C. J., and M. Zagorski. Solution structures of β peptide and its constituent fragments: relation to amyloid deposition. Science ( Washington D. C.) 253: 179-182 (1991).
23. Tomski, S. J., and R. M. Murphy. Kinetics of aggregation of synthetic β-amyloid peptide. Arch. Biochem. Biophys. 294:630-638 (1992).
24. Burdick, D., B. Soreghan, M. Kwon, J. Kosmoski, M. Knauer, A. Henschen, J. Yates, C. Cotman, and C. Glabe. Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs. J. Biol Chem. 267:546-554 (1992).
25. Hilbich, C., B. Kisters-Woike, J. Reed, C. L. Masters, and K. Beyreuther. Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease. J. Mol. Biol. 218:149-163 (1991).
26. Frazier, P. E., J. T. Nguyen, W. K. Surewicz, and D. Kirschner. pH-dependent structural transitions of Alzheimer amyloid peptides. Biophys. J. 60:1190-1201 (1991).
27. Fuson, K. S., B. D. Gitter, G. Becker, and P. C. May. Time-dependent alterations in neurotoxicity across multiple lots of amyloid β peptide (Aβ). Neurosci. Soc. Abstr. 19:832 (1993).
28. Seubert, P., C. Vigo-Pelfry, F. Esch, M. Lee, H. Dovey, D. Davis, S. Sinha, M. Schlossmacher, J. Whaley, C. Swindlehurst, R. McCormack, R. Wolfert, D. Selkoe, I. Lieberburg, and D. Schenk. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature (Lond.) 359: 325-327 (1992).
29. Arispe, N., E. Rojas, and H. B. Pollard. Alzheimer disease amyloid β protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc. Natl. Acad. Sci USA 90:567-571 (1993).
30. Li, W. Y., and L. K. Simmons. Increased ionic conductance elicited with β amyloid peptide is dependent upon peptide secondary structure. Soc. Neurosci. Abstr. 19:1037 (1993).
31. Forloni, G., N. Angeretti, R. Chiesa, E. Monzani, M. Salmona, O. Bugiani, and F. Tagliavini. Neurotoxicity of a prion protein fragment. Nature (Lond.) 362:543-546 (1993).
32. Snow, A. D., H. Mar, D. Nochlin, R. T. Sekiguchi, K. Kimata, Y. Koike, and T. N. Wight. Early accumulation of heparan sulfate in neurons and in the beta amyloid protein containing lesions in Alzheimer's disease and Down's syndrome. Am. J. Pathol 137:1253-1270 (1990).
33. 1-antichymotrypsin is associated solely with amyloid deposits containing the β-protein and is localized in specific cells of normal and diseased brain. Neurobiol. Aging 11:123-129 (1990).
34. Strittmatter, W. J., K. H. Weisgraber, D. Y. Huang, L. Dong, G. S. Salvesen, M. Pericak-Vance, D. Schmechel, A. M. Saunders, D. Goldgaber, and A. D. Roses. Binding of human apoliprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci USA 90:8098-8102 (1993).
35. Mantyh, P., J. Ghilardi, S. Rogers, E. DeMaster, C. Allen, E. Stimson, and J. Maggio. Aluminum, iron and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide. J. Neurochem. 61:1171-1174 (1993).
36. Ghiso, J., E. Matsubara, A. Koudinov, N. Choi-Miura, M. Tomita, T. Wisniewski, and B. Frangione. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem. J. 293:27-30 (1993).